Company Analysis

Corvus Pharmaceuticals, Inc. (CRVS)

Nasdaq: CRVS · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2014
Grade5.1
◀ Past 5.1● Present 6.3▶ Future 4.1
6 est.

Who runs Corvus Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Miller Richard A Md
President and CEO. First filing Mar 2016, latest May 20, 2026, 24 filings in all.
Officers reporting now
4
of 12 people with a filing in the last fifteen months
Directors reporting now
8
23 people on the record since 2016
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Miller Richard A MdPresident and CEOMar 2016May 20, 2026none
Lea LeivChief Financial OfficerMar 2016Dec 8, 2025none
Arcara JeffreyChief Business OfficerFeb 2024Dec 8, 2025none
Jones William BentonSVP, Pharmaceutical DevelopmentMar 2016Dec 8, 2025none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Clark Ian TdirectorJan 2017Jun 15, 2026none
Grais LindadirectorJan 2019Jun 15, 2026none
Moore David ScottdirectorOct 2025Jun 15, 2026none
Thompson Peter A.directorMar 2016Jun 15, 2026none
Van Den Broek RicharddirectorApr 2025Jun 15, 2026none
Chan Andrew C.directorApr 2026Apr 27, 2026none
Orbimed Advisors LLCdirectorMar 2016Jul 1, 2025none
Orbimed Capital Gp V LLCdirectorMay 2016Jul 1, 2025none
Earlier names on the record14, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton CRVS · research, not advice